Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 3
2017 2
2018 2
2019 1
2020 2
2021 3
2022 5
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Epidemiology and treatment of multiple sclerosis in elderly populations.
Vaughn CB, Jakimovski D, Kavak KS, Ramanathan M, Benedict RHB, Zivadinov R, Weinstock-Guttman B. Vaughn CB, et al. Among authors: kavak ks. Nat Rev Neurol. 2019 Jun;15(6):329-342. doi: 10.1038/s41582-019-0183-3. Nat Rev Neurol. 2019. PMID: 31000816 Review.
Ketogenic diet: Predictors of seizure control.
Agarwal N, Arkilo D, Farooq O, Gillogly C, Kavak KS, Weinstock A. Agarwal N, et al. Among authors: kavak ks. SAGE Open Med. 2017 Jun 6;5:2050312117712887. doi: 10.1177/2050312117712887. eCollection 2017. SAGE Open Med. 2017. PMID: 28620490 Free PMC article.
Patient-reported outcomes based on discontinuation or continuous treatment with natalizumab: New York State Multiple Sclerosis Consortium (NYSMSC) study.
Jakimovski D, Kavak KS, Zakalik K, McGraw C, Gottesman M, Coyle PK, Zivadinov R, Weinstock-Guttman B; New York State Multiple Sclerosis Consortium (NYSMSC). Jakimovski D, et al. Among authors: kavak ks. J Neurol Sci. 2023 Dec 15;455:122781. doi: 10.1016/j.jns.2023.122781. Epub 2023 Nov 14. J Neurol Sci. 2023. PMID: 37979415
Impact of resilience, social support, and personality traits in patients with neuroinflammatory diseases during the COVID-19 pandemic.
Jakimovski D, Kavak KS, Longbrake EE, Levit E, Perrone CM, Bar-Or A, Benedict RH, Riley CS, De Jager PL, Venkatesh S, Walker ELS, Xia Z, Weinstock-Guttman B; Multiple Sclerosis Resilience to COVID-19 (MSReCOV) Collaborative. Jakimovski D, et al. Among authors: kavak ks. Mult Scler Relat Disord. 2022 Dec;68:104235. doi: 10.1016/j.msard.2022.104235. Epub 2022 Oct 9. Mult Scler Relat Disord. 2022. PMID: 36283322 Free PMC article.
Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age.
Jakimovski D, Kavak KS, Vaughn CB, Goodman AD, Coyle PK, Krupp L, Gottesman M, Edwards KR, Lenihan M, Perel A, Zivadinov R, Weinstock-Guttman B; New York State Multiple Sclerosis Consortium (NYSMSC). Jakimovski D, et al. Among authors: kavak ks. Mult Scler Relat Disord. 2022 Jan;57:103406. doi: 10.1016/j.msard.2021.103406. Epub 2021 Nov 16. Mult Scler Relat Disord. 2022. PMID: 34915316
20 results